Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Lorna Sampson Riden"'
Autor:
Katerina Pavenski, Jeannie Callum, Lorna Sampson Riden, Christine Cserti-Gazdewich, Tik Nga Tong, Nagina Parmar, Chantal Armali, Aziz Jiwajee, Yulia Lin, Donald R. Branch, Jacob Pendergrast, Lani Lieberman, Beth Binnington, George Tomlinson, Kezia Willie-Ramharack, Wendy Lau, Nadine Shehata
Publikováno v:
TransfusionREFERENCES. 61(4)
Background Intravenous Immune Globulin (IVIG) is used to treat numerous immune-mediated and inflammatory conditions. There is growing awareness of hemolysis, occasionally severe, as a side-effect of this therapy. While most cases are associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f266b9bb4f8c48a38486f08d8b72d5f7
https://pubmed.ncbi.nlm.nih.gov/33831225
https://pubmed.ncbi.nlm.nih.gov/33831225
Autor:
Lani Lieberman, Beth Binnington, Nadine Shehata, Donald R. Branch, Emeralda Burke-Murphy, Jacob Pendergrast, Barbara Hannach, Katerina Pavenski, Vincent Laroche, Megan Blacquiere, Yulia Lin, Kezia Willie, Jiwajee Aziz, Jeannie Callum, Wendy Lau, Christine Cserti-Gazdewich, Jill R. Storry, Lorna Sampson Riden, Åsa Hellberg, Christine W. Bruggeman, Nagina Parmar, Darinka Sakac, Tik Nga Tong, Chantal Armali, Taco W. Kuijpers, Martin L. Olsson
Publikováno v:
Blood, 131(7), 830-835. American Society of Hematology
TO THE EDITOR: Although frequently effective[1][1],[2][2] and usually benign, high-dose (2 g/kg) intravenous immunoglobulin (IVIG) therapy can result in marked red blood cell (RBC) hemolysis, which in some cases is life threatening in severity.[3][3]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c37423ab83f22e46565f0e7c728f0fac
https://doi.org/10.1182/blood-2017-07-796151
https://doi.org/10.1182/blood-2017-07-796151